Navigation Links
Delcath to Present at the Lazard Healthcare Conference on November 15
Date:11/11/2011

esults to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, CE Marking for the Generation Two system, the timing of our commercial launch in Europe, adoption, use and resulting sales, if any, for  CHEMOSAT in the EEA, our ability to successfully commercialize CHEMOSAT and the potential of the chemosaturation therapy as a treatment for patients with cancers in the liver, acceptability of the clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future Delcath system for chemosaturation in the United States and foreign markets for the same or  other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for CHEMOSAT, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
2. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
3. FDA Schedules Delcath Pre-New Drug Application Meeting Date
4. Delcath Announces Completion of Regulatory Notification Process in New Zealand
5. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
6. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
7. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
8. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
9. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
10. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
11. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company focused ... today that Daniel P. Gold , Ph.D., President and ... Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. ... New York . A live webcast of the ... will be available approximately one hour after the presentation. ...
(Date:8/4/2015)... , Aug. 4, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... and Companies" to their offering. ... drug delivery - an approach used to ... use as an alternative to oral,intravascular, subcutaneous ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
Breaking Medicine Technology:MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... Reportlinker.com announces that a new market research ... Endometrial Cancer Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0479825/Endometrial-Cancer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Endometrial Cancer Therapeutics - ... Summary GlobalData, the ...
... 14, 2011 Reportlinker.com announces that a new market ... Bronchitis Therapy Area Pipeline Report ... Pipeline Report contains detailed information on the bronchitis drug ... of bronchitis drugs by company and by stage as ...
Cached Medicine Technology:Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds Bronchitis Therapy Area Pipeline Report 2
(Date:8/4/2015)... ... August 04, 2015 , ... Exsurco Medical, ... of Tissue Banks (AATB) as an Affiliate Member. Exsurco Medical finds this ... to save and improve lives by promoting the safety, quality and availability of ...
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon ... (EKG), echocardiogram, and NCV testing, announced their collegiate division, Wimbledon U , ... cardiovascular abnormalities one program at a time. , “Wimbledon U welcomes ...
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in it ... of women every year. Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. ... takes the scary unknown out of menopause. , Myth #1: Menopause only affects ...
(Date:8/4/2015)... Diego, CA (PRWEB) , ... August 04, 2015 ... ... the Rise of Local Food,” scheduled for Nov. 3 – 4, 2015, at ... grow food sustainably, create new businesses, improve food access, and manage resources efficiently ...
(Date:8/4/2015)... , ... August 04, 2015 , ... 24/7 Care ... Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of Veteran’s ... that 24/7 Care At Home’s agency is well on the path to meeting the ...
Breaking Medicine News(10 mins):Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3
... By Jenifer Goodwin and Alan Mozes HealthDay Reporters ... the District of Columbia made progress in reducing their rate ... raise the overall U.S. score from a near-failing ,D, grade, ... Dimes ranks each state according to its rate of ...
... Australian Government has named Walter and Eliza Hall Institute researcher ... The Science Minister,s Prize for Life Scientist of the ... advances, or has the potential to advance, human welfare. ... Medicine division, will be presented with the award tonight by ...
... pericytes that have not been high on the list of ... crucial role in the development of neurodegenerative diseases than has ... Neuron , cast the pericyte in a surprising new role ... and protecting sensitive brain tissue from harmful substances. By manipulating ...
... study show that patients suffering back pain get quicker ... first examination. Traditionally, patients face long and anxiety-ridden wait ... initial examination by a spine surgeon. Results from the ... examined by a Nurse Practitioner were significantly shorter, ranging ...
... , WEDNESDAY, Nov. 17 (HealthDay News) -- The ... Wednesday on the safety of caffeinated alcoholic beverages that ... hospitalized. The announcement comes amid a growing backlash ... even though such beverages are becoming increasingly popular with ...
... HealthDay Reporter , TUESDAY, Nov. 16 (HealthDay News) ... drinks are at significantly higher risk for becoming alcohol-dependent, ... weekly drinkers of energy drinks are more likely to ... Amelia M. Arria, director of the Center on Young ...
Cached Medicine News:Health News:Still Too Many Preterm Births in U.S., Report Finds 2Health News:Still Too Many Preterm Births in U.S., Report Finds 3Health News:Still Too Many Preterm Births in U.S., Report Finds 4Health News:Dr. Benjamin Kile named 2010 Australian Life Scientist of the Year 2Health News:The pericyte becomes a player in Alzheimer's, other diseases 2Health News:The pericyte becomes a player in Alzheimer's, other diseases 3Health News:The pericyte becomes a player in Alzheimer's, other diseases 4Health News:Toronto Western Hospital study demonstrates improved wait times for patients suffering back pain 2Health News:FDA Expected to Ban Caffeinated Alcohol Drinks 2Health News:Energy Drinks May Fuel College Kids' Alcohol Use 2Health News:Energy Drinks May Fuel College Kids' Alcohol Use 3
ELISA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
... a direct competitive EIA for the quantitative ... plasma. A specific agent displaces Estradiol from ... binding. Estradiol then reacts successively with an ... and alkaline phosphatase labelled Estradiol . An ...
... Estradiol (E2) concentration in human serum or plasma. ... a phenolic A ring. This steroid hormone ... is the most potent natural Estrogen, produced mainly ... by the adrenal cortex, and the male testes. ...
Medicine Products: